BioSpace News Archive

Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and year ended March 31, 2024.

Cytek Biosciences, Inc., a leading cell analysis solutions company, officially announced its Enhanced Small Particle Detection Option for its flagship Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems.

City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine to build and fund a stem cell research laboratory on its Duarte, California, campus that will further expand its scientific capabilities.

Telix Pharmaceuticals Limited announces the successful completion of CUPID1, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer.

Arrowhead Pharmaceuticals, Inc. announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society 2024 International Conference.

HaemaLogiX Ltd is pleased to announce the appointment of Professor the Hon Greg Hunt, former Australian Federal Minister for Health, to the HaemaLogiX Board as a Non-Executive Director.

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex ® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use.

Bionomics Limited announced that Spyridon “Spyros” Papapetropoulos, M.D., PhD, President and Chief Executive Officer of Bionomics will be giving an oral presentation and presenting two posters about BNC210 as a potential treatment for social anxiety disorder and post-traumatic stress disorder at the 2024 American Society of Clinical Psychopharmacology Annual Meeting taking place May 28 – 31 in Miami Beach, Florida.

Dyne Therapeutics, Inc. announced positive clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 and its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.

Aveanna Healthcare Holdings Inc. today announced that its management team will attend the UBS Healthcare Services Cape Cod Summit in Chatham, MA on Tuesday, June 4, 2024, and the Jefferies Global Healthcare Conference in New York on Wednesday, June 5, 2024.